機能性便秘症の治療における腸内細菌叢移植とプレバイオティクスの併用の有効性と安全性
機能性便秘の治療におけるマイクロバイオータ移植とプレバイオティクス併用の有効性と安全性
Chronic constipation is a common gastrointestinal disorder with a global prevalence of approximately 15%, severely impacting daily life and quality of life. It also increases the mortality rate from hypertension, cardiovascular diseases, and ischemic stroke, and is closely related to the incidence of colorectal cancer, making it a major chronic disease that seriously threatens people's health and quality of life. With the increasing aging population and lifestyle factors such as sedentary behavior and low-fiber diets, the incidence of functional constipation is gradually rising. Traditional treatment of chronic constipation mainly relies on various types of laxatives, which have significant side effects with long-term use and relatively high treatment costs, while surgical treatment has limited patient acceptance. Gut microbiota is closely related to intestinal motility, and patients with chronic constipation often have gut microbiota dysbiosis, with significant differences in gut microbiota diversity and colonic mucosal microbiota structure compared to healthy individuals. In recent years, more and more studies have found that intestinal microbiota-based therapies such as probiotics, prebiotics, synbiotics, postbiotics, and fecal microbiota transplantation (FMT) can effectively prevent and treat chronic constipation. FMT, as a method to reshape the gut microbiota, has been widely used in many centers at home and abroad, for diseases including inflammatory bowel disease, irritable bowel syndrome, autism, and obesity. The overall adverse reaction rate in clinical applications is approximately 3%, mainly consisting of abdominal discomfort (bloating, abdominal pain), diarrhea, and secondary intestinal infections or even bacteremia (rare). Our center has established a fecal microbiota transplantation center at Beijing Sixth Hospital within our medical alliance. We have currently performed nearly 100 cases of FMT for the treatment of IBD, autism, functional bowel diseases, and other metabolic diseases, with a clinical efficacy rate of 64-85% for functional constipation and constipation-predominant irritable bowel syndrome. This project aims to validate an intervention strategy combining fecal microbiota transplantation (FMT) with prebiotics primarily composed of high dietary fiber, based on the theoretical framework developed by the team led by Diwei Zheng at the Institute of Process Engineering, Chinese Academy of Sciences.The team found that the core microbiota playing a major role in the FMT process determines the therapeutic efficacy of FMT on diseases.These core microbial communities can produce acetic acid and butyric acid, which are important metabolites that not only reduce inflammatory levels and improve intestinal barrier function, but also provide energy for intestinal epithelial cells. Additionally, they effectively limit the growth of opportunistic pathogens by acidifying the intestinal environment, exerting antibacterial effects, and utilizing niche effects.Therefore, when the core microbiota occupies a dominant ecological niche in the gut, the gut microbiota can support health from multiple aspects including nutrition, immunity, metabolism, and psychology. Prebiotics designed based on the characteristics of the core microbiota can significantly enhance the activity and colonization of the core microbiota.This study aims to reconstruct a healthy intestinal ecosystem through FMT and prebiotics. Simultaneously, it proposes a "co-localization" strategy, which involves physically mixing prebiotics with core microbiota during transplantation to coexist synergistically. This approach enhances the metabolic function of core microbiota more efficiently locally, promotes the production of key metabolites such as acetic acid and butyric acid, and improves the intestinal microenvironment.Compared with the traditional stepwise model of 'microbiota transplantation + prebiotic intervention', this approach can significantly reduce the dosage of prebiotics, thereby further enhancing the safety and tolerability of the intervention.This clinical study is designed as an open-label, single-arm trial, aiming to enroll 19 patients with refractory functional constipation to receive "core microbiota transplantation based on co-localization".The study will focus on evaluating the therapeutic efficacy of the treatment in improving constipation symptoms, systematically assessing its safety, and comprehensively evaluating the level of gut microbiota remodeling through microbiome and metabolome approaches.The implementation of this project will provide clinical evidence for exploring the application of core microbiota therapy in functional bowel disorders such as constipation, and lay the foundation for optimizing and promoting microecological intervention strategies.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- 適用できない
連絡先と場所
研究連絡先
研究連絡先
- 名前:Pengguang Yan
- 電話番号:+8618810309887
- メール:pengchengf@mail.sdu.edu.cn
研究場所
-
-
-
Beijing、中国
- Peking Union Medical College Hospital
-
コンタクト:
- Pengguang Yan
- 電話番号:+8618810309887
- メール:pengchengf@mail.sdu.edu.cn
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Diagnosed with functional constipation (FC) according to Rome IV criteria.
- Symptoms persisting for at least 6 months, with criteria met for the last 3 months.
- Ineffective response to traditional treatments (dietary intervention, at least 2 types of laxatives, or probiotics).
- Willing to discontinue other constipation medications, herbal medicines, or supplements during the study.
Exclusion Criteria:
- History or clinical evidence of mechanical bowel obstruction (e.g., tumor or hernia).
- Diagnosis of megarectum, megacolon, or pseudo-obstruction.
- Organic intestinal abnormalities (obstruction, stenosis, cancer) or inflammatory bowel disease (IBD).
- Progressive colorectal polyps requiring treatment.
- History of gastrointestinal or abdominal surgery within the past 3 months.
- Severe cardiovascular or cerebrovascular diseases.
- Clinically significant liver function abnormalities (ALT/AST > 2x ULN, TBIL ≥ 1.5x ULN).
- Pregnancy, lactation, or planning to conceive during the study.
- Inability to undergo colonoscopy or catheter placement.
- Participation in other clinical trials within the past 3 months.
- Other health conditions deemed unsuitable by the investigator.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Fecal Microbiota Transplantation (FMT) combined with Prebiotics
Participants will receive a "co-localization" intervention combining Fecal Microbiota Transplantation (FMT) and prebiotics. The FMT graft is derived from screened healthy donors and processed to ensure a total viable bacterial count of ≥ 2.5×10¹² CFU. Before administration, the microbiota is physically mixed and resuspended with the prebiotic preparation according to standard procedures to enhance colonization and metabolic function. |
In this group, antibiotics are administered for 3 days prior to the procedure. A colonoscopy is performed, and a catheter is placed in the ileocecal region. Bacterial infusion is performed for 3 days with 100 mL graft per day. The graft is prepared using a "co-localization" strategy: before infusion, the microbiota is physically mixed and resuspended with the prebiotic preparation according to standard procedures. Blood and stool samples are collected before and after fecal microbiota transplantation (FMT), and researchers conduct follow-up evaluations of the patients' abdominal symptoms and signs. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in complete spontaneous bowel movements (CSBM)
時間枠:4 weeks
|
Effect of FMT combined with prebiotics preparation on the change in complete spontaneous bowel movements (CSBM) of refractory functional constipation |
4 weeks
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Frequency of SBM and CSBM
時間枠:Baseline through Week 8
|
Number of Spontaneous Bowel Movements (SBM) and Complete Spontaneous Bowel Movements (CSBM) per week. |
Baseline through Week 8
|
|
Bristol Stool Form Scale (BSFS) Score
時間枠:Baseline through Week 8
|
Assessment of stool consistency using the BSFS (scale 1-7). |
Baseline through Week 8
|
|
Patient Assessment of Constipation Symptoms Score
時間枠:Baseline, Week 4, and Week 8
|
Self-evaluation of constipation symptom severity. |
Baseline, Week 4, and Week 8
|
|
Colonic Transit Time
時間枠:Baseline and Week 4
|
Assessed by colonic transit test to evaluate intestinal motility. |
Baseline and Week 4
|
|
Fecal Water Content and Microbiota Composition
時間枠:Baseline, Week 4, and Week 8
|
Measurement of fecal water percentage and analysis of gut microbiota structure. |
Baseline, Week 4, and Week 8
|
|
Incidence of Adverse Events
時間枠:From enrollment through Week 8
|
Number of participants with adverse events (e.g., bloating, infection). |
From enrollment through Week 8
|
協力者と研究者
協力者
協力者
捜査官
捜査官
- スタディチェア:Jingnan Li, MD, Ph.D、Peking Union Medical College Hospital
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- I-25PJ3047
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。